With its recognised expertise in successfully commercializing decentralised testing and reporting for pan-cancer solid and hematological tumor analysis in precision oncology, OncoDNA has been selected as a dedicated partner to assist KU Leuven in implementing a comprehensive, scalable, end-to-end and commercially viable solution as part of the ONCNGS PCP study which is entering in phase 3. This solution (GIPXplorePLUZ) enables sensitive, non-invasive pan-cancer profiling using circulating tumor cell-free DNA (cfDNA) and will be integrated into OncoDNA’s performant CE-IVDD and GDPR proof data analytics OncoKDM® platform.
Jean-Pol Detiffe Founder of OncoDNA comments: “We are thrilled to be back for this final stage of the ONCNGS consortium, shaping the future of liquid biopsy in Europe. Our decentralized solution goes beyond analyzing 600 or 700 genes, where we will be incorporating fragmentomics signatures for advanced cancer detection and monitoring.
Prof. Vermeesch comments: “We have been exploring cfDNA patterns for over 15 years. Being able to bring a concept from the bench to the clinic is teamwork. We are excited to collaborate with OncoDNA to create the best approaches for cfDNA based cancer detection and bring that to the European and world-wide community. This will help in beating cancer!’
About OncNGS
Increasing the use of Next Generation Sequencing (NGS) in oncology requires further cost and technology acceleration to make the best solutions available to all types of patients. In the oncNGS project, 8 health procurers from 5 countries (BE, FR, DE, ES, IT) plan to launch a pre-commercial procurement to develop an NGS tumour-marker analysis kit applicable to all tumour types. The aim is that the kit will include automated data analysis, interpretation and reporting to support decision-making.
OncNGS Phase 3 officially started at the beginning of January 2025 and will run over the next 15 months. During this period, the selected suppliers will demonstrate the clinical performance of their prototypes in real-world clinical settings. Testing will be conducted both at the suppliers’ facilities and across seven pilot sites.
About GIPXplorePLUZ developed by the KU Leuven
GIPXplorePLUZ is a comprehensive scalable end-to-end solution enabling sensitive non-invasive pan-cancer profiling using circulating-tumor cell-free DNA (cfDNA) for precision oncology. Our approach results in a cost-efficient and fast, sensitive off-the-shelf massive parallel sequencing-based liquid biopsy biomarker solution.
Based on multi-modal profiling of ctDNA, it enables non-invasive predictive, prognostic and diagnostic pan-cancer solid and hematological tumor analysis. Decentralized testing and cloud-based analysis platform maximizes independence of different users, while enabling standardized reporting and knowledge sharing. By collaborating with OncoDNA – a dedicated partner that has an established value in the precision medicine market and integrating GIPXplorePLUZ into OncoDNAs’ performant CE-IVDD and GDPR-proof data analytics platform (OncoKDM®) will pave the road for an accurate non-invasive diagnostic tool to be swiftly commercialized and integrated across
Europe/European hospitals.
Disclaimer:
This is part of the oncNGS Project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme.
Timeline
